Abstract

The rapid evolution of SARS-CoV-2 is driven in part by a need to evade the antibody response in the face of high levels of immunity. Here, we isolate spike (S) binding monoclonal antibodies (mAbs) from vaccinees who suffered vaccine break-through infections with Omicron sub lineages BA.4 or BA.5. Twenty eight potent antibodies are isolated and characterised functionally, and in some cases structurally. Since the emergence of BA.4/5, SARS-CoV-2 has continued to accrue mutations in the S protein, to understand this we characterize neutralization of a large panel of variants and demonstrate a steady attrition of neutralization by the panel of BA.4/5 mAbs culminating in total loss of function with recent XBB.1.5.70 variants containing the so-called ‘FLip’ mutations at positions 455 and 456. Interestingly, activity of some mAbs is regained on the recently reported variant BA.2.86.

Many emerging SARS-CoV-2 variants partially escape the humoral immune response. Here, Liu et al. characterize 28 antibodies from BA.4/5 breakthrough infections and find attrition of neutralization and complete loss of function for variants with Spike mutations at positions 455 and 456.

Details

Title
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
Author
Liu, Chang 1   VIAFID ORCID Logo  ; Das, Raksha 2 ; Dijokaite-Guraliuc, Aiste 2   VIAFID ORCID Logo  ; Zhou, Daming 3   VIAFID ORCID Logo  ; Mentzer, Alexander J. 4   VIAFID ORCID Logo  ; Supasa, Piyada 2 ; Selvaraj, Muneeswaran 2 ; Duyvesteyn, Helen M. E. 5 ; Ritter, Thomas G. 6   VIAFID ORCID Logo  ; Temperton, Nigel 7   VIAFID ORCID Logo  ; Klenerman, Paul 8 ; Dunachie, Susanna J. 9   VIAFID ORCID Logo  ; Paterson, Neil G. 10   VIAFID ORCID Logo  ; Williams, Mark A. 10   VIAFID ORCID Logo  ; Hall, David R. 10   VIAFID ORCID Logo  ; Fry, Elizabeth E. 5   VIAFID ORCID Logo  ; Mongkolsapaya, Juthathip 11   VIAFID ORCID Logo  ; Ren, Jingshan 5   VIAFID ORCID Logo  ; Stuart, David I. 12   VIAFID ORCID Logo  ; Screaton, Gavin R. 1   VIAFID ORCID Logo 

 University of Oxford, Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Nuffield Department of Medicine, Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Oxford, Nuffield Department of Medicine, Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Oxford, Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); The Wellcome Centre for Human Genetics, Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Oxford, UK (GRID:grid.270683.8) (ISNI:0000 0004 0641 4511); Zhejiang University, College of Life Sciences, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 University of Oxford, Nuffield Department of Medicine, Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440) 
 The Wellcome Centre for Human Genetics, Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Oxford, UK (GRID:grid.270683.8) (ISNI:0000 0004 0641 4511) 
 Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440) 
 University of Kent and Greenwich Chatham Maritime, Viral Pseudotype Unit, Medway School of Pharmacy, Kent, UK (GRID:grid.9759.2) (ISNI:0000 0001 2232 2818) 
 Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440); Peter Medawar Building for Pathogen Research, Oxford, UK (GRID:grid.510993.7); University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); NIHR Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.454382.c) (ISNI:0000 0004 7871 7212) 
 Oxford University Hospitals NHS Foundation Trust, Oxford, UK (GRID:grid.410556.3) (ISNI:0000 0001 0440 1440); Peter Medawar Building for Pathogen Research, Oxford, UK (GRID:grid.510993.7); University of Oxford, Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand (GRID:grid.501272.3) (ISNI:0000 0004 5936 4917) 
10  Harwell Science & Innovation Campus, Diamond Light Source Ltd, Didcot, UK (GRID:grid.18785.33) (ISNI:0000 0004 1764 0696) 
11  University of Oxford, Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Nuffield Department of Medicine, Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand (GRID:grid.501272.3) (ISNI:0000 0004 5936 4917) 
12  University of Oxford, Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); The Wellcome Centre for Human Genetics, Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Oxford, UK (GRID:grid.270683.8) (ISNI:0000 0004 0641 4511); Harwell Science & Innovation Campus, Diamond Light Source Ltd, Didcot, UK (GRID:grid.18785.33) (ISNI:0000 0004 1764 0696) 
Pages
3284
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3039629052
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.